Methods and compositions for treating glaucoma

By identifying the visual field defect rate in glaucoma patients and administering Fas inhibitors to modulate Fas-mediated signal transduction, the problem of insufficient improvement in visual field function in existing treatments was solved, resulting in significant improvement in visual field function and vision protection.

CN123124989APending Publication Date: 2026-11-17ONL THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202580029140.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-02-28
Filing Date
2025-02-26
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Current glaucoma treatments are ineffective in improving visual field function, leading to irreversible vision loss.

Method used

By identifying an individual's historical visual field defect rate and administering Fas inhibitors, such as peptides containing the amino acid sequence HHIYLGAVNYIY, Fas-mediated signaling is modulated, Fas-mediated inflammation is inhibited, and retinal tissue is protected.

Benefits of technology

It significantly improved visual field function, slowed down vision decline, and delayed the progression of optic nerve damage.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123124989A_ABST
    Figure CN123124989A_ABST
Patent Text Reader

Abstract

This article provides a method for identifying individuals with an increased likelihood of responding to improved visual field results after glaucoma therapy, and a method for treating glaucoma in the eyes of individuals with an increased likelihood of responding to improved visual field results using glaucoma therapy. For example, this article provides a method for identifying individuals with an increased likelihood of responding to improved visual field results after glaucoma therapy, which includes: determining the historical visual field defect rate of the eyes of individuals with glaucoma; and determining the historical visual field defect rate to be approximately -0.5 dB / year or less.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-references This application claims the benefit of U.S. Provisional Patent Application No. 63 / 559,129, filed February 28, 2024, which is incorporated herein by reference in its entirety. Background Technology

[0002] Vision typically depends on maintaining the anatomical and histological integrity of the eye's internal structures. Changes in anatomical and histological homeostasis can provide causes of decreased and / or lost vision. Glaucoma is a progressive eye condition characterized by damage to the optic nerve, which often leads to irreversible vision loss. Defects in the photoreceptor cells within the eye cause abnormal changes in eye structures, such as the retina, which can lead to decreased and / or lost vision. Summary of the Invention

[0003] In some embodiments, this document provides a method for identifying individuals with an increased likelihood of responding to improved visual field function after treatment with glaucoma therapy, the method comprising: (a) determining a historical visual field defect rate in the eyes of the individual suffering from glaucoma; and (b) identifying the historical visual field defect rate as being between about -3 and about -1 dB / year. In some embodiments, the method further comprises: (c) administering the glaucoma therapy to the individual having the historical visual field defect rate between about -3 and about -1 dB / year. In some embodiments, the glaucoma therapy comprises a Fas inhibitor. In some embodiments, the Fas inhibitor is a peptide comprising the amino acid sequence HHIYLGAVNYIY or a variant thereof, or a pharmaceutically acceptable salt of said peptide.

[0004] In some embodiments, this document provides a method for treating glaucoma in an individual's eye, the method comprising: (a) identifying the individual as having a historical visual field defect rate of about -0.5 dB / year or less (e.g., about -1 dB / year or less, or between about -3 and about -1 dB / year); and (b) administering a peptide or a pharmaceutically acceptable salt of the peptide to the eye, wherein the peptide comprises the amino acid sequence HHIYLGAVNYIY or a variant thereof.

[0005] In some implementations, this document provides a method for identifying individuals who have an increased likelihood of responding with improved visual field function after treatment with glaucoma therapy, the method comprising determining the historical visual field defect rate of the eye of the individual with glaucoma and identifying the historical visual field defect rate as approximately -1 dB / year or lower.

[0006] In some embodiments, the individual is identified as having a moderate baseline sensitivity deficit at at least one point in the visual field of the eye. In some embodiments, the moderate baseline sensitivity deficit at at least one point in the visual field is about -20 to about -5 dB.

[0007] In some embodiments, the method further includes administering the glaucoma therapy to the individual having a historical visual field defect rate of about -1 dB / year or lower. In some embodiments, the historical visual field defect rate is about -3 to about -1 dB / year. In some embodiments, the glaucoma therapy includes a Fas inhibitor. In some embodiments, the Fas inhibitor is a peptide comprising the amino acid sequence HHIYLGAVNYIY or a variant thereof.

[0008] In some embodiments, this document provides a method for identifying individuals with an increased likelihood of responding to improved visual field function after treatment with glaucoma therapy, the method comprising: determining a baseline sensitivity deficit at at least one point in the visual field of the eye of the individual suffering from glaucoma; and identifying the baseline sensitivity deficit at the at least one point in the visual field as a moderate baseline sensitivity deficit of about -3 dB or less at the at least one point in the visual field. In some embodiments, the moderate baseline sensitivity deficit at the at least one point in the visual field is about -20 to about -5 dB.

[0009] In some embodiments, the individual is identified as having a historical visual field defect rate of -1 dB / year or lower. In some embodiments, the individual is identified as having a historical visual field defect rate of approximately -3 to approximately -1 dB / year.

[0010] In some embodiments, the method further includes administering the glaucoma therapy to the individual having the moderate baseline sensitivity of approximately -3 dB or lower. In some embodiments, the glaucoma therapy comprises a Fas inhibitor. In some embodiments, the Fas inhibitor is a peptide comprising the amino acid sequence HHIYLGAVNYIY or a variant thereof.

[0011] In some embodiments, this document provides a method for treating glaucoma in an individual's eye, the method comprising identifying the individual as having a historical visual field defect rate between -3 and about -1 dB / year, and administering a peptide or a pharmaceutically acceptable salt of the peptide to the eye.

[0012] In some implementations, identifying an individual with a historical visual field defect rate between about -3 and about -1 dB / year includes selecting the individual with a historical visual field defect rate between about -3 and about -1 dB / year for treatment with the peptide.

[0013] In some embodiments, the individual is identified as having a moderate baseline sensitivity deficit at at least one point in the visual field of the individual's eye. In some embodiments, the moderate baseline sensitivity deficit at at least one point in the visual field is -3 dB or less. In some embodiments, the moderate baseline sensitivity deficit at at least one point in the visual field is from about -20 to about -5 dB.

[0014] In some embodiments, this document provides a method for treating glaucoma in an individual's eye, the method comprising identifying that the individual has a moderate baseline sensitivity deficit of about -20 to about -5 dB at at least one point in the visual field of the individual's eye; and administering a peptide or a pharmaceutically acceptable salt of the peptide to the eye.

[0015] In some embodiments, identifying an individual as having a moderate baseline sensitivity deficit of about -20 to about -5 dB at at least one point in the visual field includes selecting the individual as having the moderate baseline sensitivity deficit of about -20 to about -5 dB at at least one point in the visual field.

[0016] In some embodiments, the individual is identified as having a historical visual field defect rate of -1 dB / year or lower. In some embodiments, the individual is identified as having a historical visual field defect rate of approximately -3 to approximately -1 dB / year.

[0017] In some embodiments, the peptide comprises the amino acid sequence HHIYLGAVNYIY or a variant thereof. In some embodiments, the variant sequence of the peptide comprises an amino acid substitution. In some embodiments, the variant sequence comprises one amino acid substitution.

[0018] In some embodiments, the peptide further comprises modifications. In some embodiments, the modifications comprise modified amino acids. In some embodiments, the peptide comprises an amidated C-terminus.

[0019] In some embodiments, the peptide has the structure of Formula I or a pharmaceutically acceptable salt thereof. In some embodiments, the peptide has the structure of Formula III or a pharmaceutically acceptable salt thereof.

[0020] In some embodiments, the method includes administering a pharmaceutically acceptable salt. In some embodiments, the pharmaceutically acceptable salt is an acetate. In some embodiments, the pharmaceutically acceptable salt is a polyacetate. In some embodiments, the pharmaceutically acceptable salt is a triacetate. In some embodiments, the pharmaceutically acceptable salt is a hydrochloride.

[0021] In some embodiments, the method includes administering a first dose and a second dose of the peptide or a pharmaceutically acceptable salt of the peptide. In some embodiments, the second dose is administered approximately 10 weeks or longer after the administration of the first dose. In some embodiments, the second dose is administered approximately 12 weeks after the administration of the first dose.

[0022] In some embodiments, the method includes applying a composition containing the peptide.

[0023] In some embodiments, the composition (e.g., each composition or a combination of the first dose and / or the second dose) further comprises a surfactant. In some embodiments, the surfactant is a polysorbate, a polyethoxylated castor oil derivative, a polyethoxylated fatty acid, a polyethoxylated alcohol, a polyoxyethylene-polyoxypropylene block copolymer, or an oxyethylated tert-octylphenol formaldehyde polymer. In some embodiments, the surfactant comprises about 0.01% to about 20% by weight of the composition. In some embodiments, the surfactant comprises about 0.05% to about 10% by weight of the composition.

[0024] In some embodiments, the composition (e.g., each composition or a composition of the first dose and / or the second dose) further comprises a tension modifier, a buffer, or a combination thereof. In some embodiments, the composition is buffered to a pH of 2.5 to 7.5.

[0025] In some embodiments, the composition (e.g., each composition or the composition of the first dose and / or the second dose) contains about 25 micrograms (ug or µg) to about 250 ug of the peptide.

[0026] In some embodiments, the peptide or a pharmaceutically acceptable salt thereof has a half-life in vitreous fluid exceeding about 30 days (e.g., at least 30 days). In some embodiments, the method includes using the vitreous fluid as a reservoir to deliver the peptide or a pharmaceutically acceptable salt thereof to the retinal tissue of the eye. In some embodiments, the peptide or a pharmaceutically acceptable salt thereof remains in the vitreous fluid for more than about 30 days after administration.

[0027] In some implementations, the glaucoma includes elevated intraocular pressure.

[0028] In some embodiments, the field of view is a Humphrey field of view. In some embodiments, the field of view is measured using a Humphrey field of view analyzer. In some embodiments, cluster analysis is used to measure the field of view to generate measurements of local (e.g., specific regions within the eye) field of view.

[0029] In some embodiments, the treatment includes improving the visual field function outcome of the individual's eye. In some embodiments, the visual field function outcome includes subglobal measurements of local (e.g., specific regions within the eye) visual field measurements. In some embodiments, measuring the visual field function outcome includes generating local visual field measurements within the eye. Attached Figure Description

[0030] The novel features of the invention are particularly set forth in the appended claims. A better understanding of the features and advantages of the invention will be obtained by referring to the following detailed description of illustrative embodiments utilizing the principles of the invention, along with the accompanying drawings, in which: Figure 1 Data provided showed a low association between the subject’s historical Humphrey visual field (HVF) loss rate per year and the patient’s baseline sensitivity to visible light stimulation intensity; Figure 2A Data were provided showing the relationship between the subjects’ historical HVF deficit rate / year and the subjects’ annual change in HVF, indicating that the subjects with the greatest improvement in annual change in HVF had a historical HVF deficit rate between -3 and -1 dB / year, and patients who received 50 ug and 100 ug doses of the Fas inhibitor ONL1204 both showed improvement. Figure 2B Data from objects with historical HVF rates between -3 and -1 dB / year are provided, showing the relationship between the object's historical HVF deficit rate / year and the annual variation of the object's HVF.

[0031] Figure 3A Example grayscale images of the object's retinal sensitivity are provided, where black represents low retinal sensitivity and white represents high sensitivity; Figure 3B A schematic diagram of the retinal region is provided, in which retinal sensitivity readings at various points on the retina are averaged to provide cluster measurements; Figure 3C Provided Figure 3A The annual variation of point values ​​for each retinal cluster and baseline sensitivity are shown in the figure. Figure 4A This shows the relationship between historical HVF loss rate / year and HVF change rate / year after treatment visual field clustering. Figure 4B This data shows the relationship between historical HVF loss rate / year in visual field clusters and baseline sensitivity; collectively, these data indicate that treatment with the Fas inhibitor ONL1204 can improve the rate of HVF change at all points in all visual field clusters. Figure 5AThe association between baseline sensitivity and HVF change rate / year was provided after treatment of various points in the visual field of subjects who received 100 μg of the Fas inhibitor ONL1204 and whose historical HVF loss rate was between -3 and -1 dB / year. Figure 5B The association between these two variables was low for subjects receiving 100 μg of the Fas inhibitor ONL1204 and whose historical HVF loss rate was not in the range of -3 to -1 dB / year. Figure 6A The association between baseline sensitivity and HVF change rate / year was provided after treatment of various points in the visual field of subjects who received 50 μg of the Fas inhibitor ONL1204 and whose historical HVF deficit rate was between -3 and -1 dB / year. Figure 6B The association between these two variables was low for subjects receiving 50 μg of the Fas inhibitor ONL1204 and whose historical HVF loss rate was not in the range of -3 to -1 dB / year. Figure 7A The association between baseline sensitivity and HVF change rate per year was provided after treatment of points in the field of vision of subjects who received sham treatment and whose historical HVF deficit rate was between -3 and -1 dB / year. Figure 7B The association between the two same variables was provided for subjects who received sham treatment and whose historical HVF deficit rate was not in the range of -3 to -1 dB / year. The association between baseline sensitivity and HVF change rate was low in both sham treatment groups. Figure 8A The study showed an association between baseline sensitivity and HVF change rate per year after treatment of visual field clusters in subjects with historical HVF loss rates between -3 and -1 dB / year; in contrast, Figure 8B The study showed that after treating visual field clusters in subjects whose historical HVF loss rate was not in the range of -3 to -1 dB / year, the association between the subjects’ baseline sensitivity and HVF change rate / year was low. Figure 9A The association between baseline sensitivity and HVF change rate / year was provided after treatment of visual field clusters in subjects who received 100 ug of the Fas inhibitor ONL1204 and whose historical HVF loss rate was between -3 and -1 dB / year. Figure 9B The association between these two variables was low in subjects receiving 100 μg of the Fas inhibitor ONL1204 and whose historical HVF loss rate was not in the range of -3 to -1 dB / year; and Figure 10AThe association between baseline sensitivity and HVF change rate / year was provided after treatment of visual field clusters in subjects who received 50 μg of the Fas inhibitor ONL1204 and whose historical HVF loss rate was between -3 and -1 dB / year. Figure 10B The association between these two variables was low for subjects receiving 50 μg of the Fas inhibitor ONL1204 and whose historical HVF loss rate was not in the range of -3 to -1 dB / year.

[0032] Figure 11 An exemplary treatment plan for testing the safety and efficacy of the Fas inhibitor ONL1204 is described.

[0033] Figure 12A and Figure 12B This study demonstrated that the mean change from baseline (CFB) in the thickness of the retinal nerve fiber layer (RNFL) was increased in eyes treated with ONL1204 compared to the control sham injection and the untreated contralateral eyes of subjects in all treatment groups.

[0034] Figure 13A and Figure 13B This study demonstrated that the mean CFB thickness in the upper outer quadrant of the eye treated with ONL1204 increased over time compared to the control sham injection and the untreated contralateral eye of subjects in all treatment groups.

[0035] Figure 14A , Figure 14B , Figure 14C , Figure 14D and Figure 14E This describes the mean rate change of HVF at all points or the mean total point deviation (TD) over time for all patients in the subjects treated with ONL1204 or control sham injections, or patients with a specific moderate baseline sensitivity defect and / or a historical HVF defect rate at at least one point in the visual field. Detailed Implementation

[0036] This document describes and illustrates, by way of improving visual function (e.g., visual field improvement), identifying patients who respond to glaucoma treatments. Therefore, in some embodiments, methods are provided for selecting and / or identifying patients who have an increased likelihood of responding to glaucoma treatments by exhibiting improved visual function (e.g., contrary to cessation and / or reduction of visual impairment). In these embodiments, the treatments include Fas inhibitors, such as Fas inhibitors having the structure shown in Formula I as described herein.

[0037] This article provides Fas inhibitors for modulating (e.g., inhibiting, preventing, and / or reducing) Fas-mediated signaling. In some cases, Fas inhibitors are used to treat, inhibit, prevent, and / or reduce Fas-mediated inflammation. In some cases, inhibiting, preventing, and / or reducing Fas-mediated inflammation can treat and / or prevent RNFL thinning.

[0038] In some embodiments, the Fas inhibitors described herein comprise Met-derived peptides and / or fragments thereof. In some embodiments, the Met protein, also known as c-Met or hepatocyte growth factor receptor (HGF receptor), is encoded by the Met gene (NCBI gene ID 4233, location: NC_000007.14 (116672196..116798386), UniProtKB - P0858). The Met protein comprises two major subunits: α and β subunits, and Met and fragments of Met (including the extracellular domain of Met and its α subunit) have been shown to bind to Fas and prevent apoptosis. In some embodiments, the Fas inhibitor comprises a Fas repressive peptide.

[0039] The function of Fas inhibitors and / or Fas repressor peptides can be determined by in vitro assays. For example, in some embodiments, Fas inhibitors and / or Fas repressor peptides competitively bind to the Fas receptor (FasR) with Fas ligand (FasL). In some embodiments, Fas inhibitors and / or Fas repressor peptides inhibit, reduce, or prevent caspase 8 activation in FasL-treated cells (e.g., as measured by a commercially available luminescent tetrapeptide cleavage assay kit (Promega, Madison, WI)). In some embodiments, Fas inhibitors and / or Fas repressor peptides inhibit, reduce, or prevent cell death in FasL-treated cells. Further, as an example, in some embodiments, Fas inhibitors and / or Fas repressor peptides competitively bind to the Fas receptor (FasR) with Fas activating antibodies (e.g., Fas agonist Jo2 monoclonal antibodies (BD Biosciences, San Jose, CA)). In some embodiments, Fas inhibitors and / or Fas-inhibiting peptides inhibit, reduce, or prevent caspase 8 activation in cells treated with Fas-activated antibodies (e.g., as measured by a commercially available luminescent tetrapeptide cleavage assay kit (Promega, Madison, WI)). In some embodiments, Fas inhibitors and / or Fas-inhibiting peptides inhibit, reduce, or prevent cell death in cells treated with Fas-activated antibodies. In some embodiments, the Fas inhibitor is a peptide, polypeptide (e.g., FasR or FasL), an antibody binding to FasR, an inhibitory oligonucleotide (e.g., siRNA, RNAi, antisense oligonucleotide), or an antibody binding to FasL.

[0040] In some embodiments, the Fas inhibitors described herein comprise Met-derived compounds containing the amino acid HHIYLGAVNYIY (His-His-Ile-Tyr-Leu-Gly-Ala-Val-Asn-Tyr-Ile-Tyr) (e.g., SEQ ID NO: 1-8). In some embodiments, the peptide comprises the amino acid sequence HHIYLGAVNYIY or a variant thereof.

[0041] As used herein, peptides include and / or refer to any of the various natural or synthetic compounds comprising two or more amino acids linked by peptide bonds, wherein the peptide bond links the carboxyl group of one amino acid to the amino group of another. Also as used herein, amino acids refer to and / or include naturally occurring amino acids, non-natural amino acids, amino acid analogs, and amino acid mimics, which are functionally similar to naturally occurring amino acids. Amino acids are generally represented herein by their names, commonly known three-letter symbols, or single-letter symbols recommended by the IUPAC-IUB Committee on Biochemistry Nomenclature.

[0042] In some embodiments, the Fas inhibitor peptide (e.g., a peptide comprising the amino acid sequence HHIYLGAVNYIY) comprises one or more naturally occurring amino acids. In some embodiments, the Fas inhibitor peptide (e.g., a peptide comprising the amino acid sequence HHIYLGAVNYIY) is composed of naturally occurring amino acids. As used herein, naturally occurring amino acids include and / or refer to amino acids found in nature and not artificially manipulated. In some implementations, naturally occurring amino acids include and / or also refer to 20 conventional amino acids: alanine (A or Ala), cysteine ​​(C or Cys), aspartic acid (D or Asp), glutamic acid (E or Glu), phenylalanine (F or Phe), glycine (G or Gly), histidine (H or His), isoleucine (I or Ile), lysine (K or Lys), leucine (L or Leu), methionine (M or Met), asparagine (N or Asn), proline (P or Pro), glutamine (Q or Gln), arginine (R or Arg), serine (S or Ser), threonine (T or Thr), valine (V or Val), tryptophan (W or Trp), and tyrosine (Y or Tyr).

[0043] In some embodiments, the Fas inhibitor comprises a variant sequence of a peptide (e.g., a peptide containing the amino acid sequence HHIYLGAVNYIY). In some embodiments, amino acid substitutions can be made in the sequence of any polypeptide described herein without necessarily reducing or eliminating its activity. Accordingly, in some embodiments, the variant sequence comprises one or more amino acid substitutions. In some embodiments, the variant sequence comprises one amino acid substitution. In some embodiments, the variant sequence comprises two amino acid substitutions. In some embodiments, the variant sequence comprises three amino acid substitutions. In some embodiments, the substitutions include conservative substitutions (e.g., substitution with an amino acid with similar chemical properties). In some embodiments, a nonpolar amino acid can be substituted and replaced by another nonpolar amino acid, wherein the nonpolar amino acid includes alanine, leucine, isoleucine, valine, glycine, proline, phenylalanine, tryptophan, and methionine. In some embodiments, a neutrally charged polar amino acid can be substituted and replaced by another neutrally charged polar amino acid, wherein the neutrally charged polar amino acid includes serine, threonine, cysteine, tyrosine, asparagine, and glutamine. In some embodiments, a positively charged amino acid may be substituted for another positively charged amino acid, including arginine, lysine, and histidine. In some embodiments, a negatively charged amino acid may be substituted for another negatively charged amino acid, including aspartic acid and glutamic acid. Examples of amino acid substitution also include replacing the corresponding D-amino acid with an L-amino acid, replacing homocysteine ​​with cysteine, or other non-natural amino acids.

[0044] In some embodiments, the Fas inhibitor peptide (e.g., a peptide comprising the amino acid sequence HHIYLGAVNYIY) contains one or more non-natural amino acids. In some embodiments, the Fas inhibitor peptide (e.g., a peptide comprising the amino acid sequence HHIYLGAVNYIY) is composed of non-natural amino acids. As used herein, non-natural and / or unnatural amino acids include and / or refer to amino acid structures that cannot be biosynthesized in any organism using unmodified or modified genes from any organism. In some embodiments, non-natural and / or unnatural amino acids also include and / or refer to amino acid residues not present in naturally occurring (wild-type) Met protein sequences. For example, these include, but are not limited to, modified amino acids and / or amino acid analogs (e.g., non-natural side-chain variant sequence amino acids) that are not one of the 20 naturally occurring amino acids, D-amino acids, homotype amino acids, β-homotype amino acids, N-methyl amino acids, α-methyl amino acids, or... To further illustrate, non-natural amino acids include 4-benzoylphenylalanine (Bpa), aminobenzoic acid (Abz), aminobutyric acid (Abu), aminohexanoic acid (Ahx), aminoisobutyric acid (Aib), citrulline (Cit), diaminobutyric acid (Dab), diaminopropanoic acid (Dap), diaminopropionic acid (Dap), γ-carboxyglutamic acid (Gla), homoalanine (Hala), homoarginine (Harg), homoasparagine (Hasn), homoaspartic acid (Hasp), homocysteine ​​(Hcys), homoglutamic acid (Hglu), homoglutamine (Hgln), homoisoleucine (Hile), homoleucine (Hleu), homomethionine (Hmet), homophenylalanine (Hphe), and homoserine (Hs). The non-natural amino acid residues include homotyrosine (Htyr), homovaline (Hval), hydroxyproline (Hyp), isoperidinic acid (Inp), naphthylalanine (Nal), piperidine carboxylic acid (Nip), leucine (Nle), valine (Nva), octahydroindole-2-carboxylic acid (Oic), penicillamine (Pen), phenylglycine (Phg), pyroglutamic acid (Pyr), sarcosine (Sar), tert-butylglycine (Tle), and tetrahydroisoquinoline-3-carboxylic acid (Tic). These non-natural amino acid residues can be introduced by substituting naturally occurring amino acids and / or by inserting non-natural amino acids into the sequence of naturally occurring (wild-type) Met proteins. Non-natural amino acid residues can also be incorporated to endow apelin peptide molecules with desired functionality, such as the ability to link functional moieties (e.g., PEG).

[0045] In some embodiments, the variant sequence contains one or more amino acid deletions. In some embodiments, the variant sequence contains one amino acid deletion. In some embodiments, the variant sequence contains two amino acid deletions. In some embodiments, the variant sequence contains three amino acid deletions. In some embodiments, the variant sequence contains four amino acid deletions. In some embodiments, the variant sequence contains one or more additional amino acids. In some embodiments, the additional amino acids are derived from the Met sequence. In some embodiments, the variant sequence contains substitutions and deletions. In some embodiments, the variant sequence contains substitutions and one or more additional amino acids. In some embodiments, the substitutions comprise native or non-native amino acids. In some embodiments, the variant sequence is a retro-inverted amino acid sequence. In some embodiments, the variant sequence contains one or more additional amino acid residues (e.g., one, two, or three additions) at the N or C terminus. In some embodiments, the variant sequence contains one or more amino acid residue deletions (e.g., one, two, or three deletions) at the N or C terminus.

[0046] The functionality of variant sequences of peptides (e.g., variant sequences of the amino acid sequence HHIYLGAVNYIY) can be determined by in vitro assays. For example, in some embodiments, the variant sequence competes with the Fas ligand (FasL) for binding to the Fas receptor (FasR). In some embodiments, the variant sequence inhibits, reduces, or prevents caspase 8 activation in cells treated with FasL (e.g., as measured by a commercially available luminescent tetrapeptide cleavage assay kit (Promega, Madison, WI)). In some embodiments, the variant sequence inhibits, reduces, or prevents cell death in cells treated with FasL. Further, as an example, in some embodiments, the variant sequence competes with a Fas-activating antibody (e.g., a Fas-activating Jo2 monoclonal antibody (BDBiosciences, San Jose, CA)) for binding to the Fas receptor (FasR). In some embodiments, the variant sequence inhibits, reduces, or prevents caspase 8 activation in cells treated with a Fas-activating antibody (e.g., as measured by a commercially available luminescent tetrapeptide cleavage assay kit (Promega, Madison, WI)). In some embodiments, the variant sequence inhibits, reduces, or prevents cell death in cells treated with Fas-activated antibodies. Accordingly, in some embodiments, the Fas inhibitor comprises a variant sequence of a peptide (e.g., a peptide containing the amino acid sequence HHIYLGAVNYIY) (e.g., any of the variant sequences described herein), wherein the variant sequence competitively binds to the Fas receptor (FasR) with a Fas ligand (FasL). In some embodiments, the Fas inhibitor comprises a variant sequence of a peptide (e.g., a peptide containing the amino acid sequence HHIYLGAVNYIY) (e.g., any of the variant sequences described herein), wherein the variant sequence inhibits, reduces, or prevents caspase 8 activation in cells treated with FasL. In some embodiments, the Fas inhibitor comprises a variant sequence of a peptide (e.g., a peptide containing the amino acid sequence HHIYLGAVNYIY) (e.g., any of the variant sequences described herein), wherein the variant sequence inhibits, reduces, or prevents cell death in cells treated with FasL. In some embodiments, the Fas inhibitor comprises a variant sequence of a peptide (e.g., a peptide containing the amino acid sequence HHIYLGAVNYIY) (e.g., any of the variant sequences described herein), wherein the variant sequence competitively binds to the Fas receptor (FasR) with the Fas-activating antibody. In some embodiments, the Fas inhibitor comprises a variant sequence of a peptide containing the amino acid sequence HHIYLGAVNYIY (e.g., any of the variant sequences described herein), wherein the variant sequence inhibits, reduces, or prevents caspase 8 activation in cells treated with the Fas-activating antibody.In some embodiments, Fas inhibitors include variant sequences of peptides comprising the amino acid sequence HHIYLGAVNYIY (e.g., any of the variant sequences described herein), wherein the variant sequences inhibit, reduce, or prevent cell death in cells treated with Fas-activated antibodies.

[0047] The peptide or its variant sequences may also contain one or more modifications. In some embodiments, the peptide (e.g., containing the amino acid sequence HHIYLGAVNYIY or a variant sequence thereof) contains a modification. In some embodiments, the peptide is a modified peptide. As used herein, a modified or altered peptide includes and / or refers to a modification of one or more amino acids in the peptide. In some embodiments, the type of modification of the stereoisomers. Consider all stereoisomers of the above-described compounds, in the form of mixtures or in pure or substantially pure forms. The compound may have an asymmetric center on any atom. Therefore, peptide compounds or components thereof may exist in enantiomers or diastereomers or mixtures thereof. The invention contemplates the use of any racemic mixture (i.e., a mixture containing equal amounts of each enantiomer), an enantiomer-enriched mixture (i.e., a mixture enriched with one enantiomer), a pure enantiomer or diastereomer, or any mixture thereof. The chiral center may be designated as R or S or R, S or d, D, I, L or d, I, D or L. Compounds containing amino acid residues include residues of D-amino acids, L-amino acids, or racemic derivatives of amino acids. Compounds containing sugar residues include residues of D-sugars, L-sugars, or racemic derivatives of sugars. Non-limiting examples of modifications include phosphorylation, glycosylation, ubiquitination, nitrosation, methylation, acetylation, amidation, or lipidation. Modifications can be introduced at the C-terminus, N-terminus, or any position in between of the peptide. Therefore, modified or modified peptides include and / or refer to modifications at the free amino terminus and / or carboxyl terminus (N-terminus and C-terminus, respectively). In some embodiments, N-terminal modifications include, but are not limited to, acetylation, formylation, pyroglutamylation, urea addition, lipidation, sulfonamideation, and alkylamineation. In some embodiments, C-terminal modifications include, but are not limited to, amidation, esterification, and the introduction of an aldehyde group. In some embodiments, the modification includes amidation. In some embodiments, the amidation is located at the C-terminus. In some embodiments, the modification comprises an inverted peptide (e.g., YIYNVAGLYIHH). In some implementations, the modification alters the chirality of one or more amino acid residues in the peptide (e.g., changing an L amino acid to a D amino acid).

[0048] Accordingly, in one embodiment, this document provides a peptide comprising the sequence (a)-HHIYLGAVNYIY-(b) (SEQ ID NO: 1) or (a)-YIYNVAGLYIHH-(b) (SEQ ID NO: 2), or a variant thereof, wherein: (a) is -H, -OH, -NH2, G 1 (CH2) n- R 1 CONH- or R 2 O-; (b) is -H, -CH2OH, or -CH2OR 2 -CHO, -CO2R 2 -CONH2, -CONHR 2 -CON(R) 3 2. -CONH(CH2) y NR( 3 2、-(CH2) n -G 1 -COCH2-G 1 -CONHCH2-G 1 -(CH2) n NH2、-(CH2) n NHR 2 -(CH2) n N(R 3 )2, NH-Glu-His-OH, NH-Glu-His-NH2, -Ala-His-NH2, -Gly-His-NH2, -NH-Glu-His-OH, -NH-Glu-His-NH2, -Ala-His-NH2, - Gly-His-NH2, -NH-[D]Glu-[D]-His-OH, -NH-[D]Glu-[D]-His-NH2, -[D]Ala-[D]-His-NH2, -Gly-[D]-His-NH2 or -CONH(CH2) n -G 2 G 1 Each occurrence is independently -H, -C(=O)NH2, or -C(=O)NHR. 2 -C(=O)N(R) 3 2. C(=O)OR 2 or -C(=O)R 1 G 2 Each occurrence is an NR containing at least one tertiary amine functional group within the ring. 2 4-7 membered heterocycles, or -N(R) 3 )2-substituted 3-7 membered carbon rings; R 1 Each occurrence is independently H or C. 1-6 Alkyl group, -(CH2) x (OCH2CH2) m OR 5 C 1-6-alkoxy or L; R 2 It is C independently each time it appears. 1-6 Alkyl, OR 5 or NR 5 2 replaced by C 2-6 Alkyl group, -(CH2) x (OCH2CH2) m OR 5 Or L; L, each time it appears, is a polyvalent polyethylene glycol derivative with 2-4 ends, each end of which can be independently converted by H, R 5 End sealing; R 3 It is C independently each time it appears. 1-6 Alkyl, OR 5 or N(R) 5 )2 replaced by C 2-6 Alkyl group, -(CH2) x (OCH2CH2) m OR 5 ; Or two Rs 3 Together with the N atoms they are attached to, they can form 4-8 quinary monocyclic rings or 6-10 quinary fused, bridged, or spirobicyclic rings, which may include at most two independent rings selected from -O-, -(C=O)-, and NR-. 6 Groups of S, SO or SO2; R 4 It is C independently each time it appears. 1-6 Alkyl, C 1-6 Acyl or -OPO3(R) 5 )2; R 5 It is independently H or C each time it appears. 1-6 alkyl; R 6 It appears as H or C each time. 1-6 Alkyl, C 2-6 Hydroxyalkyl, C 1-6 Alkoxy-, C 1-6 Alkyl or C 1-6 Acyl group; m = 1-100; n = 0-3; x = 0-6; and y = 2-4, Where R 1 and R 2 At most one of them is L.

[0049] In some cases, this article provides peptides containing the structure of Formula I or Formula II, or pharmaceutically acceptable salts thereof. in: A is -H, -OH, -NH2, G 1 (CH2) n- R 1 CONH- or R 2 O-; B represents -H, -CH2OH, or -CH2OR. 2 -CHO, -CO2R 2 -CONH2, -CONHR 2 -CON(R) 3 2. -CONH(CH2) y N(R 3 2、-(CH2) n- G 1 -COCH 2- G 1 -CONHCH 2- G 1 -(CH2) n NH2、-(CH2) n NHR 2 -(CH2) n N(R 3 )2, NH-Glu-His-OH, NH-Glu-His-NH2, -Ala-His-NH2, -Gly-His-NH2, NH-Glu-His-OH, NH-Glu-His-NH2, -Ala-His-NH2, -Gly-His-NH2, NH-[D]Glu-[D]-His-OH, NH-[D]Glu-[D]-His-NH 2 , -[D]Ala-[D]-His-NH2, -Gly-[D]-His-NH2 or CONH(CH2) n- G 2 ; E is independently -H, -OH, or -OR each time it appears. 4 , SH, -SR 4 Or halogen; G 1 Each occurrence is independently -H, -C(=O)NH2, or -C(=O)NHR. 2 -C(=O)N(R) 3 2. C(=O)OR 2 or -C(=O)R1 ; G 2 Each occurrence is an NR containing at least one tertiary amine functional group within the ring. 2 4-7 membered heterocycles, or N(R) 3 )2-substituted 3-7 membered carbon rings; Q is independently 1-propyl, 2-propyl, 2-methyl-propyl-2-yl, C each time it appears. 3-6 -cycloalkyl, C 4-6 -cycloalkenyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothienyl-2-yl, tetrahydrothienyl-3-yl, tetrahydropyran-2-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydrothienyl-2-yl, tetrahydrothienyl-3-yl, tetrahydrothienyl-4-yl or 1-CH(OR) 5 CH3; R 1 Each occurrence is independently H or C. 1-6 Alkyl group, -(CH2) x (OCH2CH2) m OR 5 C 1-6 alkoxy or L; R 2 It is C independently each time it appears. 1-6 Alkyl, OR 5 or N(R) 5 )2 replaced by C 2-6 Alkyl group, -(CH2) x (OCH2CH2) m OR 5 Or L; L, each time it appears, is a polyvalent polyethylene glycol derivative with 2-4 ends, each end of which can be independently converted by H, R 5 Another molecular capping of a peptide of formula I or II; R 3 It is C independently each time it appears. 1-6 Alkyl, OR 5 or N(R) 5 )2 replaced by C 2-6 Alkyl group, -(CH2) x (OCH2CH2) m OR 5 ; Or two Rs 3 Together with the N atoms they are attached to, they can form 4-8 quinary monocyclic rings or 6-10 quinary fused, bridged, or spirobicyclic rings, which may include at most two independent rings selected from -O-, -(C=O)-, and NR-. 6 Groups of S, SO or SO2; R 4 It is C independently each time it appears. 1-6 Alkyl, C 1-6 Acyl or -OPO3(R) 5 )2; R 5 It is independently H or C each time it appears. 1-6 alkyl; R 6 It appears as H or C each time. 1-6 Alkyl, C 2-6 Hydroxyalkyl, C 1-6 Alkoxy-, C 1-6 Alkyl or C 1-6 Acyl group; m = 1-100; n = 0-3; x = 0-6; and y = 2-4, Where R 1 and R 2 At most one of them is L.

[0050] In some embodiments, a peptide having the structure of Formula III or a pharmaceutically acceptable salt thereof is provided: In some implementations, a peptide having the structure of formula IV or a pharmaceutically acceptable salt thereof is provided: In some embodiments, a peptide having the formula V structure or a pharmaceutically acceptable salt thereof is provided: In some embodiments, a peptide having the structure of formula VI or a pharmaceutically acceptable salt thereof is provided: In some embodiments, a peptide having the structure of formula VII or a pharmaceutically acceptable salt thereof is provided: In some embodiments, a peptide having the structure of formula VIII or a pharmaceutically acceptable salt thereof is provided: In some implementations, a peptide having the structure of formula IX or a pharmaceutically acceptable salt thereof is provided: This document also provides salts for inhibiting Fas-mediated inflammation of the eye and for peptides used in the methods described herein. As used herein, salt is generally synonymous with pharmaceutically acceptable salt and / or includes or refers to pharmaceutically acceptable salt. Examples of pharmaceutically acceptable salts are salts with organic or inorganic acids, such as (but not limited to) acetic acid, aspartic acid, benzenesulfonic acid, benzoic acid, butyric acid, citric acid, fumaric acid, hydrochloric acid, hydrobromic acid, lactic acid, maleic acid, malonic acid, methanesulfonic acid, 4-methylbenzenesulfonic acid, nicotinic acid, phosphoric acid, succinic acid, sulfuric acid, or tartaric acid, prepared using methods well known in the art. In some embodiments, the salt is a hydrochloride salt.

[0051] Furthermore, these salts can be prepared by adding inorganic or organic bases to free acids. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, primary, secondary, and tertiary amines, substituted amines (including naturally occurring substituted amines), cyclic amines, and salts of basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N-ethylpiperidine, piperidine, and polyamine resins.

[0052] Salts and pharmaceutically acceptable salts are described in J. Pharmaceutical Sciences, 66: 1-19 (1977), the contents of which are incorporated herein by reference.

[0053] In some embodiments, the salt is an acetate. In some embodiments, the acetate is a polyacetate. In some embodiments, the polyacetate is a triacetate.

[0054] In one embodiment, a pharmaceutical composition comprising a Fas inhibitory peptide (also referred to as a composition) is also provided. In some embodiments, the pharmaceutical compositions described herein comprise a peptide (e.g., a peptide comprising the amino acid sequence HHIYLGAVNYIY) or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical compositions described herein comprise a peptide comprising the amino acid sequence HHIYLGAVNYIY or a variant thereof, or a pharmaceutically acceptable salt of said peptide. In some embodiments, the pharmaceutical compositions described herein comprise a peptide having the structure of any one of formulas I-IX or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical compositions described herein comprise a peptide having the structure of formula I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical compositions described herein comprise a peptide having the structure of formula III or a pharmaceutically acceptable salt thereof.

[0055] Pharmaceutical compositions may contain one or more excipients. As used herein, excipients include and / or refer to any pharmaceutically acceptable additive, carrier, diluent, excipient, or other ingredient other than the active pharmaceutical ingredient (API), which is typically included in a formulation and / or administered to a patient. Pharmaceutical compositions may contain a single pharmaceutical formulation (e.g., extended release, immediate release, delayed release, nanoparticles, etc.) or multiple formulations (e.g., immediate and delayed release, nanoparticles and non-nanoparticles, etc.). Excipients also include and / or refer to agents that can be added to a formulation to provide desired consistency (e.g., modify volume properties), to improve stability, and / or to adjust the mass permeation molar concentration. Examples of commonly used excipients include, but are not limited to, sugars, polyols, amino acids, surfactants, and polymers. In some embodiments, as used herein, nonionic or non-ionizable excipients include and / or refer to agents without a net charge.

[0056] In some embodiments, the nonionic excipient does not carry a net charge under certain formulation conditions, such as pH. Examples of nonionic excipients include, but are not limited to, sugars (e.g., sucrose), sugar alcohols (e.g., mannitol), and nonionic surfactants (e.g., polysorbate 80).

[0057] In some embodiments, the composition comprises excipients suitable for ocular applications. Suitable excipients include, but are not limited to, tension modifiers, preservatives, chelating agents, buffers, surfactants, solubilizers, and antioxidants. Suitable tension modifiers include mannitol, sodium chloride, glycerol, sorbitol, etc. Suitable preservatives include parabens, benzalkonium chloride, benzo[a]dodecyl ammonium bromide, polyquaternium-1, etc. Suitable chelating agents include sodium edetate, etc. Suitable buffers include phosphates, borates, citrates, acetates, tromethamine, etc. Suitable surfactants include ionic and nonionic surfactants. In some embodiments, one or more excipients include nonionic surfactants such as polysorbate, polyethoxylated castor oil derivatives, polyethoxylated fatty acids, polyethoxylated alcohols, polyoxyethylene-polyoxypropylene block copolymers (poloxam), and oxyethylated tert-octylphenol formaldehyde polymers (teroxam). Other suitable surfactants may also be included. Suitable antioxidants include sulfites, thiosulfates, ascorbic acid salts, BHA, BHT, tocopherol, etc.

[0058] In some embodiments, the composition comprises a nonionic surfactant. In some embodiments, the composition comprises polysorbate, polyethoxylated castor oil derivative, polyethoxylated fatty acid, polyethoxylated alcohol, polyoxyethylene-polyoxypropylene block copolymer (poloxam), or oxyethylated tert-octylphenol formaldehyde polymer (teroxam). In some embodiments, the composition comprises polysorbate. In some embodiments, the composition comprises polyethoxylated castor oil derivative. In some embodiments, the composition comprises polyethoxylated fatty acid. In some embodiments, the composition comprises polyethoxylated alcohol. In some embodiments, the composition comprises polyoxyethylene-polyoxypropylene block copolymer (poloxam). In some embodiments, the composition comprises oxyethylated tert-octylphenol formaldehyde polymer (teroxam).

[0059] In some embodiments, the surfactant comprises 0.01% to 20% by weight (w / w) of the composition. In some embodiments, the nonionic surfactant comprises from about 0.01% w / w to about 20% w / w of the composition. In some embodiments, the nonionic surfactant comprises at least about 0.01% w / w of the composition. In some embodiments, the nonionic surfactant comprises at most about 20% w / w of the composition. In some embodiments, the nonionic surfactant comprises approximately 0.05% w / w to approximately 0.1% w / w of the composition, approximately 0.05% w / w to approximately 0.1% w / w of the composition, approximately 0.05% w / w to approximately 0.5% w / w of the composition, approximately 0.05% w / w to approximately 1% w / w of the composition, approximately 0.05% w / w to approximately 2% w / w of the composition, approximately 0.05% w / w to approximately 5% w / w of the composition, approximately 0.05% w / w to approximately 10% w / w of the composition, approximately 0.05% w / w to approximately 20% w / w of the composition, approximately 0.1% w / w to approximately 0.5% w / w of the composition, approximately 0.1% w / w to approximately 1% w / w of the composition, and approximately 0.1% w / w to approximately 2% of the composition. w / w, about 0.1% w / w to about 5% w / w of the composition, about 0.1% w / w to about 10% w / w of the composition, about 0.1% w / w of the composition to about 20% w / w of the composition, about 0.5% w / w of the composition to about 1% w / w of the composition, about 0.5% w / w of the composition to about 2% w / w of the composition, about 0.5% w / w to about 5% w / w of the composition, about 0.5% w / w to about 10% w / w of the composition, about 0.5% w / w to about 20% w / w of the composition, about 1% w / w to about 2% w / w of the composition, about 1% w / w to about 5% w / w of the composition, about 1% w / w to about 10% w / w of the composition, about 1% w / w to about 20% w / w of the composition, about 2% w / w of the composition. w / w to about 5% w / w of the composition, about 2% w / w to about 10% w / w of the composition, about 2% w / w to about 20% w / w of the composition, about 5% w / w to about 10% w / w of the composition, about 5% w / w to about 20% w / w of the composition, or about 10% w / w to about 20% w / w of the composition.In some embodiments, the nonionic surfactant comprises about 0.05% w / w, about 0.1% w / w, about 0.5% w / w, about 1% w / w, about 2% w / w, about 5% w / w, about 10% w / w, or about 20% w / w of the composition.

[0060] In some embodiments, the nonionic surfactant comprises from about 0.05% w / w to about 2% w / w of the composition. In some embodiments, the nonionic surfactant comprises at least about 0.05% w / w of the composition. In some embodiments, the nonionic surfactant comprises at most about 2% w / w of the composition. In some embodiments, the nonionic surfactant comprises approximately 0.05% w / w to approximately 0.1% w / w of the composition, approximately 0.05% w / w to approximately 0.1% w / w of the composition, approximately 0.05% w / w to approximately 0.2% w / w of the composition, approximately 0.05% w / w to approximately 0.3% w / w of the composition, approximately 0.05% w / w to approximately 0.4% w / w of the composition, approximately 0.05% w / w to approximately 0.5% w / w of the composition, approximately 0.05% w / w to approximately 0.6% w / w of the composition, approximately 0.05% w / w to approximately 1% w / w of the composition, approximately 0.05% w / w to approximately 1.5% w / w of the composition, approximately 0.05% w / w to approximately 2% w / w of the composition, and approximately 0.1% of the composition. w / w to about 0.1% w / w of the composition, about 0.1% w / w to about 0.2% w / w of the composition, about 0.1% w / w to about 0.3% w / w of the composition, about 0.1% w / w to about 0.4% w / w of the composition, about 0.1% w / w to about 0.5% w / w of the composition, about 0.1% w / w to about 0.6% w / w of the composition, about 0.1% w / w to about 1% w / w of the composition, about 0.1% w / w to about 1.5% w / w of the composition, about 0.1% w / w to about 2% w / w of the composition, about 0.1% w / w to about 0.2% w / w of the composition, about 0.1% w / w to about 0.3% w / w of the composition. w / w, about 0.1% w / w to about 0.4% w / w of the composition, about 0.1% w / w to about 0.5% w / w of the composition, about 0.1% w / w to about 0.6% w / w of the composition, about 0.1% w / w to about 1% w / w of the composition, about 0.1% w / w to about 1.5% w / w of the composition, about 0.1% w / w to about 2% w / w of the composition, about 0.2% w / w to about 0.3% w / w of the composition, about 0.2% w / w to about 0.4% w / w of the composition, about 0.2% w / w to about 0.5% w / w of the composition, about 0.2% w / w to about 0.6% w / w of the composition, about 0.2% w / w to about 1% w / w of the composition, about 0.2% w / w to about 1.5% w / w of the composition, about 0.2% w / w to about 2% w / w of the composition, about 0.3% w / w to about 0.4% w / w of the composition, about 0.3% w / w to about 0.5% w / w of the composition, about 0.3% w / w to about 0.6% w / w of the composition, about 0.3% w / w to about 1% w / w of the composition, about 0.3% w / w to about 1.5% w / w of the composition, about 0.3% w / w to about 2% w / w of the composition, about 0.4% w / w to about 0.5% w / w of the composition, about 0.4% w / w to about 0.6% w / w of the composition, about 0.4% w / w to about 1% w / w of the composition. w / w, about 0.4% w / w to about 1.5% w / w of the composition, about 0.4% w / w to about 2% w / w of the composition, about 0.5% w / w to about 0.6% w / w of the composition, about 0.5% w / w to about 1% w / w of the composition, about 0.5% w / w to about 1.5% w / w of the composition, about 0.5% w / w to about 2% w / w of the composition, about 0.6% w / w to about 1% w / w of the composition, about 0.6% w / w to about 1.5% w / w of the composition, about 0.6% w / w to about 2% w / w of the composition, about 1% w / w to about 1.5% w / w of the composition, about 1% w / w to about 2% w / w of the composition, or about 1.5% w / w of the composition. From w / w to about 2% w / w of the composition. In some embodiments, the nonionic surfactant accounts for about 0.05% w / w, about 0.1% w / w, about 0.1% w / w, about 0.2% w / w, about 0.3% w / w, about 0.4% w / w, about 0.5% w / w, about 0.6% w / w, about 1% w / w, about 1.5% w / w, or about 2% w / w of the composition.

[0061] In some embodiments, the nonionic surfactant includes polysorbate 20, poloxamer 407, tyloxacillin, or cremophor. In some embodiments, the nonionic surfactant is polysorbate 20. In some embodiments, the nonionic surfactant is poloxamer 407. In some embodiments, the nonionic surfactant is tyloxacillin. In some embodiments, the nonionic surfactant is cremophor. The nonionic surfactants described herein may exist within any of the ranges described herein (e.g., percentage w / w), with specific values ​​falling within the described range.

[0062] In some embodiments, the composition further comprises a cosolvent (e.g., between 0.5% and 50% w / w), such as N,N-dimethylacetamide, ethanol, PEG-400, propylene glycol, dimethyl sulfoxide (DMSO); oils or cyclodextrins may be added to the pharmaceutical formulation. In some embodiments, the composition further comprises a tension modifier. In some embodiments, the composition is an isotonic solution. In some embodiments, the tension modifier is mannitol, sorbitol, glucose, or trehalose, or an inorganic salt (such as sodium chloride). In some embodiments, the composition comprises mannitol. In some embodiments, the composition comprises sorbitol. In some embodiments, the composition comprises glucose or trehalose. In some embodiments, the composition comprises an inorganic salt. In some embodiments, the tension modifier is present in an amount suitable for giving the composition a tension in the range of 250-400 mOsm / L. In some embodiments, a nonionic surfactant comprises from about 1% w / w to about 10% w / w of the composition. In some embodiments, a nonionic surfactant comprises at least about 1% w / w of the composition. In some embodiments, the nonionic surfactant accounts for up to about 10% w / w of the composition. In some embodiments, the nonionic surfactant comprises about 1% w / w to about 2% w / w of the composition, about 1% w / w to about 3% w / w of the composition, about 1% w / w to about 4% w / w of the composition, about 1% w / w to about 5% w / w of the composition, about 1% w / w to about 10% w / w of the composition, about 2% w / w to about 3% w / w of the composition, about 2% w / w to about 4% w / w of the composition, about 2% w / w to about 5% w / w of the composition, about 2% w / w to about 10% w / w of the composition, about 3% w / w to about 4% w / w of the composition, about 3% w / w to about 5% w / w of the composition, about 3% w / w to about 10% w / w of the composition, and about 4% w / w to about 5% w / w of the composition. w / w, from about 4% w / w to about 10% w / w of the composition, or from about 5% w / w to about 10% w / w of the composition. In some embodiments, the nonionic surfactant accounts for about 1% w / w, about 2% w / w, about 3% w / w, about 4% w / w, about 5% w / w, or about 10% w / w of the composition.

[0063] In some embodiments, the composition comprises a buffer. In some embodiments, the buffer is an acidifier. In some embodiments, the acidifier is an acetate buffer with pH 4.5. In some embodiments, the concentration of the pH 4.5 acetate buffer is about 10 millimoles (mM). Generally, the pH can be controlled by a suitable buffer suitable for injection into the eye; for example, the pH of the composition can be in the range of 2.5-7.5 or 3.5-4.5.

[0064] As described herein, the composition may comprise one or more excipients. Accordingly, in some embodiments, the composition comprises a nonionic surfactant, a tension modifier, and a buffer in combination with the peptide. Any of the described excipients may be combined in the described amounts and / or ranges.

[0065] In one embodiment, the composition described herein comprises an amount of a peptide suitable for inhibiting Fas-mediated inflammation and / or treating, inhibiting, and / or reducing RNFL thickness defects or their symptoms in the eye. As used herein, dosage or amount includes and / or refers to the amount of therapeutic agent (such as the described peptide) in the composition (e.g., a composition for application to the eye). Dosage may refer to (i) the peptide (parent compound) or a pharmaceutically acceptable salt thereof. In some embodiments, the amount of peptide in the composition (i.e., a pharmaceutical composition) suitable for the methods described herein (e.g., treating RNFL thinning) ranges from 5 micrograms (µg or µg) to 10,000 µg. Dosage forms comprising the compositions described herein are typically administered to the vitreous fluid of the eye and may also be formulated for injection into the eye (e.g., intravitreal injection). In some embodiments, the amount of peptide suitable for the methods described herein (e.g., a peptide comprising the amino acid sequence HHIYLGAVNYIY) or a pharmaceutically acceptable salt thereof ranges from 5 µg to 10,000 µg. In some embodiments, the amount of a peptide comprising the amino acid sequence HHIYLGAVNYIY or a variant thereof, or a pharmaceutically acceptable salt of the peptide suitable for the methods described herein, ranges from 5 μg to 10,000 μg. In some embodiments, the amount of a peptide having the structure of Formula I or a pharmaceutically acceptable salt thereof suitable for the methods described herein ranges from 5 μg to 10,000 μg. In some embodiments, the amount of a peptide having the structure of Formula III or a pharmaceutically acceptable salt thereof suitable for the methods described herein ranges from 5 μg to 10,000 μg.

[0066] In some embodiments, the dose comprises about 5-1,000 μg of a peptide (e.g., Formula III) or a variant thereof. In some embodiments, the dose comprises about 25-500 μg of a peptide or a variant thereof. In some embodiments, the dose comprises about 25-250 μg of a peptide or a variant thereof. In some embodiments, the dose comprises about 50-250 μg of a peptide or a variant thereof. In some embodiments, the dose comprises about 50 μg of a peptide or a variant thereof. In some embodiments, the dose comprises about 100 μg of a peptide or a variant thereof. In some embodiments, the dose comprises about 200 μg of a peptide or a variant thereof. In some embodiments, the dose comprises about 300 μg of a peptide or a variant thereof. In some embodiments, the peptide is present at a concentration from 0.1 mg / mL to 10 mg / mL. In some embodiments, the peptide is present at a concentration from 0.1 mg / mL to 5.0 mg / mL.

[0067] In some embodiments, the dose comprises about 5 μg of a pharmaceutically acceptable salt of a peptide to about 300 μg of a pharmaceutically acceptable salt of a peptide. In some embodiments, the dose comprises at least about 5 μg of a pharmaceutically acceptable salt of a peptide. In some embodiments, the dose comprises at most about 300 μg of a pharmaceutically acceptable salt of a peptide.

[0068] The concentration of the peptide in the composition can be adjusted in a manner suitable for ocular application. In some embodiments, the concentration of the peptide in the composition ranges from about 0.1 mg / mL to about 5 mg / mL. In some embodiments, the concentration of the peptide in the composition ranges from about 0.1 mg / mL to about 10 mg / mL. In some embodiments, the concentration of the peptide in the composition ranges from about 0.1 mg / mL to about 100 mg / mL. In some embodiments, the concentration of the peptide (e.g., a peptide comprising the amino acid sequence HHIYLGAVNYIY) or a pharmaceutically acceptable salt thereof ranges from about 0.1 mg / mL to about 5 mg / mL. In some embodiments, the concentration of the peptide comprising the amino acid sequence HHIYLGAVNYIY or a variant thereof, or a pharmaceutically acceptable salt of the peptide, ranges from about 0.1 mg / mL to about 5 mg / mL. In some embodiments, the concentration of the peptide having the structure of Formula I or a pharmaceutically acceptable salt thereof ranges from about 0.1 mg / mL to about 5 mg / mL. In some embodiments, the concentration range of the peptide having the Formula III structure or a pharmaceutically acceptable salt thereof is from about 0.1 mg / mL to about 5 mg / mL.

[0069] In some embodiments, the compositions described herein are applied to the eye of an individual in need. Application to the eye (i.e., “ocular application” or “ocular administration”) includes subconjunctival, intravitreal, retrobulbar, intraanterior chamber, subretinal, or suprachoroidal administration. In some embodiments, ocular administration includes subconjunctival, intravitreal, retrobulbar, or intraanterior chamber administration. In some embodiments, ocular administration includes intravitreal administration. In some embodiments, ocular administration includes subconjunctival administration. In some embodiments, ocular administration includes retrobulbar administration. In some embodiments, ocular administration includes intraanterior chamber administration.

[0070] In some embodiments, dosage forms comprising the compositions described herein are typically administered to the vitreous fluid of the eye. In some embodiments, the peptide (e.g., a peptide comprising the amino acid sequence HHIYLGAVNYIY) or a pharmaceutically acceptable salt thereof has a half-life in the vitreous fluid greater than about 30 days to greater than about 275 days. In some embodiments, the peptide comprising the amino acid sequence HHIYLGAVNYIY or a variant thereof, or a pharmaceutically acceptable salt thereof, has a half-life in the vitreous fluid greater than about 30 days to greater than about 275 days. In some embodiments, the peptide having the structure of Formula I or a pharmaceutically acceptable salt thereof has a half-life greater than about 30 days to greater than about 275 days. In some embodiments, the peptide having the structure of Formula III or a pharmaceutically acceptable salt thereof has a half-life greater than about 30 days to greater than about 275 days. In some embodiments, the peptide comprising the amino acid sequence HHIYLGAVNYIY or a variant thereof, or a pharmaceutically acceptable salt thereof, has a half-life greater than about 14 days to greater than about 275 days. In some embodiments, the peptide having the structure of Formula I or a pharmaceutically acceptable salt thereof has a half-life in vitreous fluid greater than about 14 days to greater than about 275 days. In some embodiments, the peptide having the structure of Formula III or a pharmaceutically acceptable salt thereof has a half-life in vitreous fluid greater than about 14 days to greater than about 275 days.

[0071] In some embodiments, the peptide has a half-life in the eye greater than about 14 days. In some embodiments, the peptide has a half-life in the eye greater than about 30 days. In some embodiments, the peptide has a half-life in the eye greater than about 60 days. In some embodiments, the peptide has a half-life in the eye greater than about 90 days. In some embodiments, the peptide has a half-life in the eye greater than about 120 days. In some embodiments, the peptide has a half-life in the eye greater than about 150 days. In some embodiments, the peptide has a half-life in the eye greater than about 180 days. In some embodiments, the peptide has a half-life in the eye greater than about 210 days. In some embodiments, the peptide has a half-life in the eye greater than about 240 days. In some embodiments, the peptide has a half-life in the eye greater than about 270 days.

[0072] In some embodiments, the peptide has a half-life greater than about 14 days in vitreous fluid. In some embodiments, the peptide has a half-life greater than about 30 days in vitreous fluid. In some embodiments, the peptide has a half-life greater than about 60 days in vitreous fluid. In some embodiments, the peptide has a half-life greater than about 90 days in vitreous fluid. In some embodiments, the peptide has a half-life greater than about 120 days in vitreous fluid. In some embodiments, the peptide has a half-life greater than about 150 days in vitreous fluid. In some embodiments, the peptide has a half-life greater than about 180 days in vitreous fluid. In some embodiments, the peptide has a half-life greater than about 210 days in vitreous fluid. In some embodiments, the peptide has a half-life greater than about 240 days in vitreous fluid. In some embodiments, the peptide has a half-life greater than about 270 days in vitreous fluid.

[0073] Determining the amount of peptides in vitreous fluid typically requires collecting all or most of the vitreous fluid from the eye, or sacrificing the eye, to sample the vitreous fluid. In some embodiments, collecting all or most of the vitreous fluid from a human eye, or sacrificing the eye, is not feasible for maintaining the health of the human eye. Accordingly, in some embodiments, the half-life of the peptide in the human eye is determined by measuring the half-life of the peptide in a mammalian eye and / or inferring the half-life of the peptide from the half-life of the peptide in a mammalian eye. In some embodiments, the mammal is a rabbit. In some embodiments, the mammal is a pig (e.g., a miniature pig). In some embodiments, the mammal is a monkey. Various methods for detecting the presence of drugs are also suitable for detecting peptides. For example, methods suitable for detecting peptides include mass spectrometry analysis of samples from vitreous fluid (e.g., liquid chromatography-mass spectrometry (LC-MS) or high-performance LC-MS (HPLC-MS)).

[0074] In some implementations, this document provides methods for treating glaucoma in an individual's eye, including glaucoma therapies (e.g., as described herein).

[0075] In some embodiments, the methods for treating glaucoma provided herein include administering glaucoma therapy to an individual with a historical visual field defect rate of about -0.5 dB / year or lower (e.g., -0.5 to -3 dB / year). In some embodiments, the individual has a historical visual field defect rate of about -1 dB / year or lower (e.g., -1 to -3 dB / year). In some embodiments, the individual has a historical visual field defect rate of about -1 to about -3 dB / year.

[0076] In some embodiments, the method of treating glaucoma provided herein includes administering glaucoma therapy to an individual having a moderate baseline sensitivity deficit at at least one point in the visual field of the eye. In some embodiments, the moderate baseline sensitivity deficit at at least one point in the visual field is -3 dB or less (e.g., -3 to -25 dB). In some embodiments, the moderate baseline sensitivity deficit at at least one point in the visual field is -5 dB or less (e.g., -5 to -25 dB). In some embodiments, the moderate baseline sensitivity deficit at at least one point in the visual field is about -3 dB to about -25 dB. In some embodiments, the moderate baseline sensitivity deficit at at least one point in the visual field is about -5 to about -20 dB. In some embodiments, the moderate baseline sensitivity deficit at at least one point in the visual field is about -10 to about -15 dB.

[0077] In some implementations, the methods for treating glaucoma provided herein include administering glaucoma therapy to an individual who has a historical visual field defect rate of about -0.5 dB / year or less (e.g., as described above) and has a moderate baseline sensitivity defect (e.g., as described above) at at least one point in the visual field of the eye.

[0078] In some embodiments, the methods for treating glaucoma provided herein include administering glaucoma therapy to an individual who, following treatment with glaucoma therapy, has an increased likelihood of responding to glaucoma therapy due to improved visual field function. In some embodiments, the methods described herein are used to identify this increased likelihood. In some embodiments, this increased likelihood is identified by determining and identifying an individual's historical visual field defect rate, identifying a moderate baseline sensitivity defect at at least one point in the visual field of the individual's eye, or a combination thereof.

[0079] In some embodiments, the likelihood of such an increase is identified by determining the historical visual field defect rate. In some embodiments, the likelihood of such an increase is identified by identifying a historical visual field defect rate of -0.5 dB / year or lower (e.g., -0.5 to -3 dB / year). In some embodiments, the likelihood of such an increase is identified by identifying a historical visual field defect rate of -1 dB / year or lower (e.g., -1 to -3 dB / year). In some embodiments, the likelihood of such an increase is identified by identifying a historical visual field defect rate of about -1 to about -3 dB / year.

[0080] In some embodiments, the likelihood of such an increase is identified by determining a baseline sensitivity deficit at at least one point in the visual field. In some embodiments, the likelihood of such an increase is identified by identifying a moderate baseline sensitivity deficit at at least one point in the visual field. In some embodiments, the likelihood of such an increase is identified by identifying a moderate baseline sensitivity deficit of -3 dB or less (e.g., -3 to -25 dB) at at least one point in the visual field. In some embodiments, the likelihood of such an increase is identified by identifying a moderate baseline sensitivity deficit of -5 dB or less (e.g., -5 to -25 dB) at at least one point in the visual field. In some embodiments, the likelihood of such an increase is identified by identifying a moderate baseline sensitivity deficit of about -3 to about -25 dB at at least one point in the visual field. In some embodiments, the likelihood of such an increase is identified by identifying a moderate baseline sensitivity deficit of about -5 to about -20 dB at at least one point in the visual field. In some embodiments, the likelihood of such an increase is identified by identifying a moderate baseline sensitivity deficit of about -10 to about -15 dB at at least one point in the visual field.

[0081] In some embodiments, individuals with a history of visual field defects are selected for glaucoma therapy. In some embodiments, individuals with moderate baseline sensitivity loss at at least one point in their visual field are selected for glaucoma therapy. In some embodiments, individuals with both a history of visual field defects and moderate baseline sensitivity loss at at least one point in their visual field are selected for glaucoma therapy.

[0082] In some embodiments, this document provides methods for identifying individuals with an increased likelihood of responding with improved visual field function after glaucoma therapy, methods including: (a) determining the historical visual field defect rate of the individual's eye; and (b) identifying the historical visual field defect rate as at most -0.5 dB / year. In some embodiments, the historical visual field defect rate is at most -1 dB / year. In some embodiments, the historical visual field defect rate is between approximately -3 and approximately -1 dB / year.

[0083] In some embodiments, the method further includes: (c) administering glaucoma therapy to an individual with a historical visual field defect rate of up to -0.5 dB / year. In some embodiments, the historical visual field defect rate is up to -1 dB / year. In some embodiments, the historical visual field defect rate is between about -3 and about -1 dB / year.

[0084] In some embodiments, the individual also has a moderate baseline sensitivity deficit at at least one individual point within the visual field. In some embodiments, the moderate baseline sensitivity deficit at at least one point within the visual field is at most -3 dB. In some embodiments, the baseline sensitivity deficit at at least one point within the visual field is at most -5 dB. In some embodiments, the moderate baseline sensitivity deficit at at least one individual point within the visual field is from about -3 dB to about -25 dB. In some embodiments, the moderate baseline sensitivity deficit at at least one individual point within the visual field is from about -5 dB to about -20 dB. In some embodiments, the moderate baseline sensitivity deficit at at least one individual point within the visual field is from about -10 dB to about -15 dB.

[0085] In some embodiments, this document provides methods for identifying individuals with an increased likelihood of responding with improved visual field function after treatment with glaucoma therapy. These methods include: (a) determining a baseline sensitivity deficit at at least one point within the visual field of the individual's eye; and (b) identifying a moderate baseline sensitivity deficit at at least one point in the visual field as at most -3 dB. In some embodiments, a moderate baseline sensitivity deficit at at least one point in the visual field is at most -5 dB. In some embodiments, a moderate baseline sensitivity deficit at at least one point in the visual field is about -25 to about -3 dB. In some embodiments, a moderate baseline sensitivity deficit at at least one point in the visual field is about -20 to about -5 dB. In some embodiments, a moderate baseline sensitivity deficit at at least one point in the visual field is about -15 to about -10 dB.

[0086] In some embodiments, the method further includes: (c) administering glaucoma therapy to an individual having a moderate baseline sensitivity deficit of up to -3 dB at at least one point in the visual field. In some embodiments, the moderate baseline sensitivity deficit at at least one point in the visual field is up to -5 dB. In some embodiments, the moderate baseline sensitivity deficit at at least one point in the visual field is about -25 to about -3 dB. In some embodiments, the moderate baseline sensitivity deficit at at least one point in the visual field is about -20 to -5 dB. In some embodiments, the moderate baseline sensitivity deficit at at least one point in the visual field is about -15 to about -10 dB.

[0087] In some implementations, an individual may also be identified as having a historical visual field defect rate. In some implementations, an individual may be identified as having a historical visual field defect rate of up to -0.5 dB / year. In some implementations, an individual may be identified as having a historical visual field defect rate of up to -1 dB / year. In some implementations, an individual may be identified as having a historical visual field defect rate of approximately -3 and approximately -1 dB / year.

[0088] In some embodiments, glaucoma therapy includes a Fas inhibitor. In some embodiments, the Fas inhibitor is a peptide comprising the amino acid sequence HHIYLGAVNYIY or a variant thereof, or a pharmaceutically acceptable salt of the peptide. In some embodiments, administration of the peptide to an individual with a glaucoma history of -0.5 dB / year or less is sufficient to treat glaucoma and improve functional visual field outcomes compared to sham injection (see [link to relevant documentation]). Figures 14C-14E In some implementations, compared to sham injections, administration of the peptide to glaucoma individuals with a historical visual field defect rate of -0.5 dB / year or lower and a moderate baseline sensitivity defect at at least one point in the visual field is sufficient to treat glaucoma and improve visual field function outcomes (see [link]). Figure 14B and Figures 14D-14E ).

[0089] In some embodiments, this document provides methods for treating glaucoma in an individual's eye, methods comprising: (a) identifying an individual with a historical visual field defect rate of at most -0.5 dB / year (e.g., at most about -1 dB / year or between about -3 and about -1 dB / year); and (b) administering a peptide or a pharmaceutically acceptable salt of a peptide to the eye, wherein the peptide comprises the amino acid sequence HHIYLGAVNYIY or a variant thereof. In some embodiments, the historical visual field defect rate is at most -1 dB / year. In some embodiments, the historical visual field defect rate is between about -3 and about -1 dB / year. In some embodiments, administration of the peptide to a glaucoma individual with a historical visual field defect rate of -0.5 dB / year or lower is sufficient to treat glaucoma and improve functional visual field outcomes compared to sham injection (see [link to relevant documentation]). Figures 14C-14E ).

[0090] In some implementations, an individual may also have a moderate baseline sensitivity deficit at at least one single point within the visual field. In some implementations, the moderate baseline sensitivity deficit at at least one point within the visual field is at most -3 dB. In some implementations, the moderate baseline sensitivity deficit at at least one point within the visual field is at most -5 dB. In some implementations, the moderate baseline sensitivity deficit at at least one single point within the visual field is from about -3 dB to about -25 dB. In some implementations, the moderate baseline sensitivity deficit at at least one single point within the visual field is from about -5 dB to about -20 dB. In some implementations, the moderate baseline sensitivity deficit at at least one single point within the visual field is from about -10 dB to about -15 dB. In some implementations, administering the peptide to an individual with a moderate baseline sensitivity deficit at at least one point within the visual field (with or without a history of visual field deficit rate of -0.5 dB / year or less) is sufficient to treat glaucoma and improve visual field function outcomes (see [link]). Figure 14B and Figures 14D-14E ).

[0091] In some embodiments, this document provides methods for treating glaucoma in an individual's eye, methods comprising: (a) identifying an individual with a moderate baseline sensitivity deficit of at least -3 dB (e.g., at least about -5 dB, or about -20 to about -5 dB) at at least one point in the visual field; and (b) administering a peptide or a pharmaceutically acceptable salt of a peptide to the eye, wherein the peptide comprises the amino acid sequence HHIYLGAVNYIY or a variant thereof. In some embodiments, the moderate baseline sensitivity deficit at at least one point in the visual field is at most -5 dB. In some embodiments, the moderate baseline sensitivity deficit at at least one point in the visual field is about -3 dB to about -25 dB. In some embodiments, the moderate baseline sensitivity deficit at at least one point in the visual field is about -5 dB to about -20 dB. In some embodiments, the moderate baseline sensitivity deficit at at least one point in the visual field is about -10 dB to about -15 dB.

[0092] In some implementations, an individual may also be identified as having a historical visual field defect rate. In some implementations, an individual may be identified as having a historical visual field defect rate of up to -0.5 dB / year. In some implementations, an individual may be identified as having a historical visual field defect rate of up to -1 dB / year. In some implementations, an individual may be identified as having a historical visual field defect rate of approximately -3 and approximately -1 dB / year.

[0093] In some embodiments, the method further includes administering a first dose and a second dose of the peptide or a pharmaceutically acceptable salt of the peptide, wherein the second composition is administered about 10 weeks or longer after the first dose. In some embodiments, the second dose is administered about 12 weeks after the first dose. In some embodiments, the first and second doses of the peptide are the same composition containing the peptide. In some embodiments, the first and second doses of the peptide are different compositions containing the peptide.

[0094] In some embodiments, the peptide or a pharmaceutically acceptable salt thereof has a half-life in vitreous fluid exceeding about 30 days (e.g., at least 30 days). In some embodiments, the method includes using vitreous fluid as a reservoir to deliver the peptide or a pharmaceutically acceptable salt thereof to retinal tissue in the eye, wherein the peptide or a pharmaceutically acceptable salt thereof remains in the vitreous fluid for more than about 30 days after administration.

[0095] In some implementations, glaucoma involves elevated intraocular pressure.

[0096] In some embodiments, the variant sequence contains an amino acid substitution. In some embodiments, the variant sequence contains one amino acid substitution.

[0097] In some embodiments, the peptide further comprises modifications. In some embodiments, the modifications comprise modified amino acids. In some embodiments, the peptide comprises an amidated C-terminus. In some embodiments, the peptide has the structure of Formula I or a pharmaceutically acceptable salt thereof. In some embodiments, the peptide has the structure of Formula III or a pharmaceutically acceptable salt thereof.

[0098] In some embodiments, the method includes administering a pharmaceutically acceptable salt. In some embodiments, the pharmaceutically acceptable salt is an acetate. In some embodiments, the pharmaceutically acceptable salt is a polyacetate. In some embodiments, the polyacetate is a triacetate. In some embodiments, the pharmaceutically acceptable salt is a hydrochloride.

[0099] In some embodiments, the method includes applying a composition comprising a peptide. In some embodiments, the composition (e.g., each composition or the first / second composition) further comprises one or more excipients. In some embodiments, the composition (e.g., each composition or the first / second composition) further comprises a surfactant. In some embodiments, the surfactant is a nonionic surfactant. In some embodiments, the surfactant is a polysorbate, a polyethoxylated castor oil derivative, a polyethoxylated fatty acid, a polyethoxylated alcohol, a polyoxyethylene-polyoxypropylene block copolymer, or an oxyethylated tert-octylphenol formaldehyde polymer. In some embodiments, the surfactant comprises about 0.01% to about 20% by weight of the composition. In some embodiments, the surfactant comprises about 0.05% to about 10% by weight of the composition. In some embodiments, the composition (e.g., each composition or the first / second composition) further comprises a tension modifier, a buffer, or a combination thereof. In some embodiments, the composition is buffered to a pH of 2.5 to 7.5. In some embodiments, the composition comprises about 25 micrograms (µg) to about 250 µg of peptide.

[0100] In some embodiments, visual field function results include subglobal measurements of local (e.g., specific regions within the eye) visual field measurements. In some embodiments, measuring visual field function results includes generating local visual field measurements within the eye. In some embodiments, cluster analysis is used to measure the visual field to generate measurements of local (e.g., specific regions within the eye) visual field measurements.

[0101] In some implementations, the treatment includes improving the individual's visual field function (see [link to treatment]). Figures 14A-14E In some implementations, (a) includes selecting individuals with a historical visual field defect rate between approximately -3 and approximately -1 dB / year for treatment with peptides (see [link]). Figure 14C , Figure 14D and Figure 14EIn some implementations, the visual field result is the Humphrey visual field. In some implementations, the visual field is measured using a Humphrey visual field analyzer.

[0102] In some implementations, the treatment includes increasing the average change in retinal nerve fiber layer (RNFL) thickness from baseline (see [link to treatment]). Figure 12A and Figure 12B In some embodiments, the treatment includes increasing the mean change in thickness of the ganglion cell complex from baseline. In some embodiments, the treatment includes increasing the mean change in thickness of the upper outer quadrant of the ganglion cell complex from baseline (see...). Figure 13A and Figure 13B ).

[0103] As used herein, inhibition or inhibiting or reducing includes and / or refers to mitigating or inhibiting a given condition, symptom, ailment, or disease, and / or reducing the baseline activity of a biological activity or process.

[0104] As used herein, "individual" is synonymous with patient and / or object and includes and / or refers to a person who has been diagnosed with a disease or condition requiring treatment as disclosed herein. However, examples are not limited to humans and include chimpanzees, marmosets, cattle, horses, sheep, goats, pigs, rabbits, dogs, cats, rats, mice, guinea pigs, etc. An individual is generally a person and can be someone who has been diagnosed with a disease or condition requiring treatment as disclosed herein.

[0105] As used herein, treating includes and / or refers to improving a disease or condition or its symptoms (e.g., slowing or halting or alleviating the development of a disease or at least one clinical symptom of it). In some embodiments, treating also includes and / or refers to reducing or improving at least one physical and / or biological parameter, including those that the patient may not be able to discern. In some embodiments, treating includes and / or refers to modulating a disease, condition, or biological process physically (e.g., stabilizing identifiable symptoms), physiologically (e.g., stabilizing physical and / or biological parameters), or both. In some embodiments, treating includes and / or refers to preventing or delaying the onset, development, or progression of a disease or condition. In some embodiments, treating includes and / or refers to preventing, delaying, or inhibiting (i) a healthy physiological state or (ii) a baseline physiological state (e.g., the progression of a disease or condition).

[0106] As used herein, “a” or “an” when used in conjunction with the term “comprising” in the claims and / or specification includes and / or refers to “a” and is also consistent with the meanings of “one or more,” “at least one,” and “one or more.” Similarly, the word “another” can mean at least a second or more.

[0107] As used herein, the terms “comprising” (and any form of inclusion, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of inclusion, such as “include” and “includes”), or “containing” (and any form of containing, such as “contain” and “contains”) are inclusive or open-ended and do not exclude additional, unlisted elements or process steps. As used herein, in any example or embodiment described herein, “comprising” may be replaced with “consisting essentially of” and / or “consisting of”. As used herein, in any example or implementation described herein, “comprises” may be replaced with “consists essentially of” and / or “consists of”.

[0108] As used herein, the term “about” in the context of a given value or range includes and / or refers to a value or range within 20% of the given value or range.

[0109] As used herein, the term “and / or” should be considered as a specific disclosure of each of two specified features or components with or without the other. For example, “A and / or B” should be considered as a specific disclosure of each of (i) A, (ii) B, and (iii) A and B, as if each were listed independently herein.

[0110] As used herein, “sample” includes and / or refers to any fluid or liquid sample that is analyzed to detect and / or quantify an analyte. In some embodiments, the sample is a biological sample. Examples of samples include, but are not limited to, bodily fluids, extracts, solutions containing proteins and / or DNA, cell extracts, cell lysates, or tissue lysates. Non-limiting examples of bodily fluids include urine, saliva, blood, serum, plasma, cerebrospinal fluid, tears, semen, sweat, pleural effusion, liquefied fecal matter, and lacrimal gland secretions.

[0111] Example Example 1 - Identification of subjects who may respond strongly to Fas inhibition therapy Target The primary objective is to determine whether subjects who may respond well to Fas inhibitors can be identified based on their historical visual field defect rates.

[0112] Research Design Patients diagnosed with open-angle glaucoma were enrolled in an escalating dose group and received two intravitreal injections (day 0 and day 90) of an acetate peptide (ONL1204) with the formula III structure. Visual function parameters were measured at two screening time points, at baseline, and approximately day 90, day 177, day 180, and day 270. Visual function measurements included visual field analysis before and after treatment with ONL1204. Randomization was stratified according to mean HVF deviation (-5.00 dB to >-10.00 dB and ≤-10.00 dB to -15.00 dB).

[0113] Visual function data were collected and analyzed, including historical Humphrey visual field (HVF) defect rate, baseline sensitivity at the start of the study, and HVF defect rate after treatment. Figure 1 Data provided showed a low association between the historical Humphrey visual field (HVF) loss rate per year and the baseline sensitivity to visible light stimulation intensity. In some analyses, data from individual points within the visual field were grouped into clusters, suggesting that only the inner and upper sectors were used as approximations to generate equivalent sectors in datasets detecting HVF and retinal nerve fiber layer (RNFL) thickness.

[0114] result Patients receiving multiple doses (including 50 ug and 100 ug ONL1204) performed well in visual field outcome analyses (e.g., suppression of decline rate or improvement in visual function, as measured by Humphrey visual field (HVF)), which included clustering trend analysis (e.g., measuring changes in local predefined regions / clusters) (see [link to relevant documentation]). Gardiner et al. Detection of Functional Change Using Cluster Trend Analysis in Glaucoma. Invest Ophthalmol Vis Sci. May 1, 2017 ).

[0115] Surprisingly, patients who showed improvement in the HVF analysis had a historical HVF deficit rate between approximately -3 and approximately -1 dB / year. Figure 2A Data were provided showing the relationship between the subjects’ historical HVF deficit rate / year and the subjects’ annual change in HVF, indicating that the subjects with the greatest improvement in annual change in HVF had a historical HVF deficit rate between -3 and -1 dB / year, and patients who received 50 ug and 100 ug doses of the Fas inhibitor ONL1204 both showed improvement. Figure 2B Data from objects with historical HVF rates between -3 and -1 dB / year are provided, showing the relationship between the object's historical HVF deficit rate / year and the annual variation of the object's HVF. Figure 3A An example grayscale image depicting the retinal sensitivity of subjects treated with 100 ug ONL1204 is shown, where black represents low retinal sensitivity and white represents high sensitivity. Figure 3B A schematic diagram of the retinal region is provided, in which retinal sensitivity readings at various points on the retina are averaged to provide cluster measurements. Figure 3C Provided with Figure 3A Annual variation of point values ​​and baseline sensitivity of retinal clusters in the same patients. Figure 4A This shows the relationship between historical HVF loss rate / year and HVF change rate / year after treatment within the visual field cluster. Figure 4B The data show the relationship between historical HVF loss rate / year in visual field clusters and baseline sensitivity; these data collectively demonstrate that treatment with the Fas inhibitor ONL1204 can improve the rate of HVF change at all points in all visual field clusters.

[0116] Figure 5A The association between baseline sensitivity and HVF change rate / year was provided after treatment of various points in the visual field of subjects who received 100 μg of the Fas inhibitor ONL1204 and whose historical HVF loss rate was between -3 and -1 dB / year. Figure 5B The association between these two variables was low for subjects receiving 100 μg of the Fas inhibitor ONL1204 and whose historical HVF loss rate was not in the range of -3 to -1 dB / year. Figure 6A The association between baseline sensitivity and HVF change rate / year was provided after treatment of various points in the visual field of subjects who received 50 μg of the Fas inhibitor ONL1204 and whose historical HVF deficit rate was between -3 and -1 dB / year. Figure 6BThe association between these two variables was low for subjects receiving 50 μg of the Fas inhibitor ONL1204 and whose historical HVF loss rate was not in the range of -3 to -1 dB / year. Figure 7A The association between baseline sensitivity and HVF change rate per year was provided after treatment of points in the field of vision of subjects who received sham treatment and whose historical HVF deficit rate was between -3 and -1 dB / year. Figure 7B The association between the two same variables was provided for subjects who received sham treatment and whose historical HVF deficit rate was not in the range of -3 to -1 dB / year. The association between baseline sensitivity and HVF change rate was low in both sham treatment groups.

[0117] Figure 8A The study showed an association between baseline sensitivity and HVF change rate per year after treatment of visual field clusters in subjects with historical HVF loss rates between -3 and -1 dB / year; in contrast, Figure 8B The study showed that after treatment of visual field clusters in subjects whose historical HVF loss rates were not in the range of -3 to -1 dB / year, the association between baseline sensitivity and HVF change rate / year was low. Figure 9A The association between baseline sensitivity and HVF change rate / year was provided after treatment of visual field clusters in subjects who received 100 ug of the Fas inhibitor ONL1204 and whose historical HVF loss rate was between -3 and -1 dB / year. Figure 9B The association between these two variables was low for subjects receiving 100 μg of the Fas inhibitor ONL1204 and whose historical HVF loss rate was not in the range of -3 to -1 dB / year. Figure 10A The association between baseline sensitivity and HVF change rate / year was provided after treatment of visual field clusters in subjects who received 50 μg of the Fas inhibitor ONL1204 and whose historical HVF loss rate was between -3 and -1 dB / year. Figure 10B The association between these two variables was low for subjects receiving 50 μg of the Fas inhibitor ONL1204 and whose historical HVF loss rate was not in the range of -3 to -1 dB / year.

[0118] In summary, these data suggest that historical HVF data can be used to identify patient populations that respond to HCV improvement, with these responders having a historical HVF deficit between -3 and -1 dB / year.

[0119] Example II - Validation of the safety and efficacy of Fas inhibitor therapy in patient studies background Based on the preliminary data presented in Example I, further clinical studies were conducted to evaluate the safety of Formula III (ONL1204) in patients with progressive open-angle glaucoma (OAG) despite good intraocular pressure control.

[0120] Eligible patients had progressive ophthalmic angiopathy (OAG) with evidence of visual field loss detected by means of: (1) a decrease in mean deviation (MD) of Humphrey visual field (HVF) of -0.5 dB / year or more, or (2) a decrease in retinal nerve fiber layer (RNFL) thickness of -1.00 µm / year or more, as detected by optical coherence tomography (OCT). Patients were randomized (2:2:1) to one of three treatment groups: (a) low dose of ONL1204 50 µg; (b) high dose of ONL1204 100 µg; and (c) sham injection. Patients in the treatment groups were given an intravitreal (IVT) injection of the appropriate dose of ONL1204 ophthalmic solution or sham injection solution on days 1 and 90. Figure 11 The study lasted approximately nine months. Randomization was stratified by baseline HVF MD (1) -5.00 dB to greater than -10.00 dB and (2) less than or equal to -10.00 dB to -15.00 dB.

[0121] The primary objective of this study was the safety and tolerability of ONL1204, with a secondary objective of assessing its efficacy using visual field and OCT.

[0122] result This study included 25 patients, including 9 in the high-dose group of ONL1204 100 µg, 10 in the low-dose group of ONL1204 50 µg, and 6 in the sham injection group.

[0123] Regarding overall safety, most reported treatment-emergent adverse events (TEAEs) were of mild to moderate severity. Four cases of vitreous opacities were reported, three in the ONL1204 100 µg high-dose group and one in the ONL1204 50 µg low-dose group. All cases were of mild to moderate severity and had no effect on intraocular pressure (IOP). In the ONL1204 50 µg low-dose group, four subjects reported serious ophthalmic TEAEs, all of which were assessed as being related to the study treatment (see Table 1). Overall, ONL1204 did not demonstrate dose-limiting toxicities.

[0124] Table 1 The effect of treatment on visual function was assessed using Humphrey 24-2 VF. No trend in baseline change (CFB) of visual impairment was observed in any of the treatment groups. However, subgroup analysis of subjects with more severe VF deficits at baseline showed a trend of improvement in eyes treated with ONL1204 compared to eyes treated with sham treatment, because compared to eyes treated with sham treatment (… Figure 12A ) or the opposite eye ( Figure 12B Compared to sham treatment, treatment with either of these two doses of ONL1204 resulted in a significant increase in RNFL. (Compared to sham-treated eyes...) Figure 13A ) or the opposite eye ( Figure 13B In comparison, similar effects on GCC thickness in the upper outer quadrant of the eye were also observed with both doses of ONL1204. These findings suggest that visual field improved or stabilized in many patients.

[0125] In addition, for each point (4 at baseline, 1 at day 90, 4 at day 180, and 4 at day 270), the total deviation (TD) value was averaged at each time point. A total of 260 points were identified in 5 patients who received sham injections; 260 points were identified in 5 patients who received 50 µg ONL1204; and 416 points were identified in 8 patients who received 100 µg ONL1204. The average point TD value was used to calculate the slope to assess change within the 270-day study period. The slope for each point was annualized to a rate of change in dB / year, and a slope was provided for each of the 52 points for each subject. The slopes were then averaged for each subject within a single treatment group to generate the average rate of change in HVF points (dB / year) for all patients using all identified HVF points. Figure 14A Based on an overall analysis of all patients at all identified HVF points, neither of the two doses of ONL1204 showed a significant difference in functional outcomes compared to sham injection.

[0126] Subgroup analyses averaged the slopes at points of moderate baseline sensitivity deficit (defined in this example as between approximately -5 dB and -20 dB) to generate the mean rate of change (dB / year) of HVF points for all patients and baseline sensitivity within a defined range at HVF points. Figure 14B This subgroup analysis identified 85 points in the sham injection group, 90 points in the ONL1204 50 µg group, and 159 points in the ONL1204 100 µg group. By observing only the changes in HVF points exhibiting moderate baseline sensitivity deficits at the start of the experiment, the data indicated that treatment with either of these two doses of ONL1204 was sufficient to increase HVF changes over time, suggesting that ONL1204 administration to this subgroup improved visual field function outcomes.

[0127] Further subgroup analysis was performed on subjects with a historical HVF defect rate worse than -1 dB / year, excluding those with a rate between -0.5 and -1.0 dB / year to exclude potentially non-progressive cases, thus generating the mean HVF point defect rate (dB / year) at all HVF points for patients with a defined historical visual field defect rate. Figure 14C A total of 208 points were identified in 4 patients in the sham injection group, 208 points in 4 patients in the ONL1204 50 µg group, and 260 points in 5 patients in the ONL1204 100 µg group. By observing changes in HVF over time only in patients with a defined historical visual field defect rate at the start of the experiment, treatment with either of these two doses of ONL1204 appeared sufficient to increase HVF over time, suggesting that ONL1204 administered to this subgroup also improved visual field function outcomes in this subgroup.

[0128] Further subgroup analysis identified patients with a historical visual field defect rate of at least -1 dB / year, and patients with the above-defined moderate baseline sensitivity defect (approximately -20 to approximately -5 dB) at each point, to generate the mean rate of change (dB / year) of HVF points for patients with both a defined historical visual field defect rate and moderate baseline sensitivity defect. Figure 14D A total of 67 points were identified in 4 patients in the sham injection group, 89 points in 50 µg patients in the ONL1204 group, and 124 points in 5 patients in the ONL1204 100 µg group. When HVF changes over time were isolated only at points showing moderate baseline sensitivity loss in patients with a defined historical visual field defect rate, the trend of increasing HVF over time was more pronounced after treatment with either of these two doses of ONL1204 compared to sham injection.

[0129] Finally, the mean TD of patients with a defined historical visual field defect rate and moderate baseline sensitivity was plotted against the time course of the study. Figure 14E These data suggest that, compared to sham injections, ONL1204 treatment in identified patients with a historical visual field defect rate of -1 dB / year and moderate baseline sensitivity loss at the HVF point typically exhibits increased total bias at each time point.

[0130] Overall, ONL1204 appears to have a greater effect in subjects with a pre-treatment history of defect rate worse than -1 dB / year or with moderate baseline sensitivity defects at the HVF point. This effect is even more pronounced when both markers are present.

[0131] in conclusion In this study, intravitreal administration of ONL1204 ophthalmic solution (50 µg and 100 µg, 90 days apart) via IVT in subjects with progressive OAG demonstrated safety and good tolerability. In the 50 µg treatment group, glaucoma worsening and increased IOP were observed in 3 subjects, leading to treatment discontinuation in 2 subjects. Analysis of OCT data showed increased RNFL and GCC layer thickness in eyes treated with ONL1204. Pointwise analysis of VF data suggested potentially increased sensitivity in areas with moderate visual field loss at baseline. These findings support further development of ONL1204 as a novel neuroprotective agent for patients with progressive OAG experiencing visual field loss of at least -0.5 dB / year.

[0132] sequence

Claims

1. A method for identifying individuals with an increased likelihood of responding to glaucoma treatment with improved visual field results, the method comprising: (a) Determine the historical visual field defect rate of the eyes of the individuals with glaucoma; as well as (b) The historical visual field loss rate is identified as -1 dB / year or lower.

2. The method according to claim 1, wherein the method further comprises: (c) Administer the glaucoma therapy to the individual with a historical visual field defect rate of -1 dB / year or lower.

3. The method according to claim 1 or 2, wherein the historical visual field loss rate is about -3 and about -1 dB / year.

4. The method according to any one of claims 1-3, wherein the individual is identified as having a moderate baseline sensitivity deficit at at least one point in the visual field of the eye.

5. The method of claim 4, wherein the moderate baseline sensitivity deficit is about -20 to about -5 dB.

6. A method for identifying individuals with an increased likelihood of responding to glaucoma treatment with improved visual field results, the method comprising: (a) Identify a baseline sensitivity defect at at least one point in the visual field of the eye of the individual suffering from glaucoma; as well as (b) The baseline sensitivity deficit was identified as approximately -3 dB or lower.

7. The method according to claim 6, wherein the method further comprises: (c) The glaucoma therapy is administered to the individuals who have a baseline sensitivity deficit of approximately -3 dB or less.

8. The method of claim 6 or 7, wherein the baseline sensitivity defect is about -20 to about -5 dB.

9. The method according to any one of claims 6-8, wherein the individual is identified as having a historical visual field defect rate of -1 dB / year or lower.

10. The method of claim 9, wherein the individual is identified as having a historical visual field defect rate of about -3 to about -1 dB / year.

11. The method according to any one of claims 1-10, wherein the glaucoma treatment comprises a Fas inhibitor.

12. The method of claim 11, wherein the Fas inhibitor is a peptide comprising the amino acid sequence HHIYLGAVNYIY or a variant thereof, or a pharmaceutically acceptable salt of said peptide.

13. A method for treating glaucoma in an individual's eye, the method comprising: (a) Identify that the individuals have a historical visual field loss rate between approximately -3 and approximately -1 dB / year; as well as (b) Applying a peptide or a pharmaceutically acceptable salt of the peptide to the eye, wherein the peptide comprises the amino acid sequence HHIYLGAVNYIY or a variant thereof.

14. The method of claim 13, wherein the treatment includes improving the visual field function of the individual's eye.

15. The method of claim 13 or 14, wherein (a) comprises selecting the individual having a historical visual field defect rate of about -3 to about -1 dB / year for treatment with the peptide.

16. The method according to any one of claims 13-15, wherein the individual is identified as having a moderate baseline sensitivity deficit at at least one point in the visual field of the eye.

17. The method of claim 15, wherein the moderate baseline sensitivity deficit is -3 dB or lower.

18. The method of claim 16, wherein the moderate baseline sensitivity deficit is about -20 to about -5 dB.

19. A method for treating glaucoma in an individual's eye, the method comprising: (a) Identify that the individual has a moderate baseline sensitivity deficit of about -20 to about -5 dB at at least one point in the visual field of the eye; as well as (b) Applying a peptide or a pharmaceutically acceptable salt of the peptide to the eye, wherein the peptide comprises the amino acid sequence HHIYLGAVNYIY or a variant thereof.

20. The method of claim 19, wherein the treatment includes improving the visual field function of the individual's eye.

21. The method of claim 19 or 20, wherein (a) comprises selecting the individual having the moderate baseline sensitivity deficit of about -20 to about -5 dB for treatment with the peptide.

22. The method according to any one of claims 1-21, wherein the field of view is the Humphrey field of view.

23. The method of claim 22, wherein the field of view is measured by a Humphrey field of view analyzer.

24. The method according to any one of claims 13-23, wherein the method further comprises administering a first dose and a second dose of the peptide or a pharmaceutically acceptable salt of the peptide, and wherein the second dose is administered about 10 weeks or longer after the administration of the first dose.

25. The method of claim 24, wherein the second dose is administered approximately 12 weeks after the first dose.

26. The method according to any one of claims 13-25, wherein the peptide or a pharmaceutically acceptable salt thereof has a half-life in vitreous fluid of more than about 30 days (e.g., at least 30 days).

27. The method according to any one of claims 13-26, wherein the method comprises using the vitreous fluid as a reservoir to provide the peptide or a pharmaceutically acceptable salt thereof to the retinal tissue of the eye, wherein the peptide or a pharmaceutically acceptable salt thereof is present in the vitreous fluid for more than about 30 days after administration.

28. The method according to any one of claims 13-27, wherein the glaucoma comprises elevated intraocular pressure.

29. The method according to any one of claims 13-28, wherein the variant sequence comprises an amino acid substitution.

30. The method of claim 29, wherein the variant sequence comprises an amino acid substitution.

31. The method according to any one of claims 13-30, wherein the peptide further comprises a modification.

32. The method of claim 31, wherein the modification comprises a modified amino acid.

33. The method according to any one of claims 13-32, wherein the peptide comprises an amidated C-terminus.

34. The method according to any one of claims 13-33, wherein the peptide has the structure of formula I or a pharmaceutically acceptable salt thereof.

35. The method according to any one of claims 13-34, wherein the peptide has the structure of formula III: (Formula III) Or its pharmaceutically acceptable salt.

36. The method according to any one of claims 13-35, wherein the method comprises administering a pharmaceutically acceptable salt thereof.

37. The method of claim 36, wherein the pharmaceutically acceptable salt is an acetate.

38. The method of claim 37, wherein the pharmaceutically acceptable salt is a polyacetate.

39. The method of claim 38, wherein the polyacetate is a triacetate.

40. The method of claim 39, wherein the pharmaceutically acceptable salt is a hydrochloride salt.

41. The method according to any one of claims 13-40, wherein the method comprises applying a composition comprising the peptide.

42. The method of claim 41, wherein the composition (e.g., each composition or the composition of the first dose and / or the second dose) further comprises one or more excipients.

43. The method according to any one of claims 41-42, wherein the composition (e.g., each composition or the composition of the first dose and / or the second dose) further comprises a surfactant.

44. The method of claim 43, wherein the surfactant is a nonionic surfactant.

45. The method according to claim 44, wherein the surfactant is a polysorbate, a polyethoxylated castor oil derivative, a polyethoxylated fatty acid, a polyethoxylated alcohol, a polyoxyethylene-polyoxypropylene block copolymer, or an oxyethylated tert-octylphenol formaldehyde polymer.

46. ​​The method according to any one of claims 43-45, wherein the surfactant comprises about 0.01% to about 20% by weight of the composition.

47. The method of claim 46, wherein the surfactant comprises about 0.05% to about 10% by weight of the composition.

48. The method according to any one of claims 41-47, wherein the composition (e.g., each composition or a composition of the first dose and / or the second dose) further comprises a tension modifier, a buffer, or a combination thereof.

49. The method according to any one of claims 41-48, wherein the composition is buffered at a pH of 2.5 to 7.

5.

50. The method according to any one of claims 41-49, wherein the composition comprises about 25 micrograms (µg or µg) to about 250 µg of the peptide.

51. The method according to any one of claims 1-50, wherein the visual field function result includes a subglobal measurement of local (e.g., a specific region within the eye) visual field measurements.

52. The method of claim 51, wherein measuring the visual field function result includes generating local visual field measurements within the eye.

53. The method according to any one of claims 1-52, wherein cluster analysis is used to measure the visual field to generate measurements of local (e.g., specific regions within the eye) visual field values.